Metabolic bone disease in inflammatory bowel disease
- Harold N Rosen, MD
Harold N Rosen, MD
- Associate Professor in Medicine
- Harvard Medical School
- Section Editors
- Marc K Drezner, MD
Marc K Drezner, MD
- Section Editor — Bone Disease
- Professor of Medicine
- University of Wisconsin Medical School
- Paul Rutgeerts, MD, PhD, FRCP
Paul Rutgeerts, MD, PhD, FRCP
- Section Editor — Inflammatory Bowel Disease
- Emeritus Professor of Medicine
- University Hospital, Leuven, Belgium
Osteoporosis is common in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) or ulcerative colitis (UC). In cross-sectional studies of patients with IBD, the prevalence of osteoporosis ranges from 18 to 42 percent [1,2]. In patients newly diagnosed with IBD, the prevalence is much lower (0 to 5 percent) .
The etiology of low bone mass is multifactorial and includes corticosteroid therapy, disease-related inflammatory activity, malabsorption, and hypogonadism [3,4].
This topic review will focus on the risk factors for and the evaluation and treatment of bone disease in patients with IBD. The diagnosis and treatment of osteoporosis in pre- and postmenopausal women and men and the prevention and treatment of glucocorticoid-induced osteoporosis are reviewed elsewhere. (See "Evaluation and treatment of premenopausal osteoporosis" and "Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women" and "Overview of the management of osteoporosis in postmenopausal women" and "Clinical manifestations, diagnosis, and evaluation of osteoporosis in men" and "Treatment of osteoporosis in men" and "Prevention and treatment of glucocorticoid-induced osteoporosis".)
Bone mineral density — In cross-sectional studies, osteoporosis (T-score <-2.5) has been noted in approximately 18 to 42 percent of patients with established IBD [1,2]. The prevalence of osteopenia (T-score between -1 and -2.5) ranges from 22 to 77 percent . In some [5-8], but not all [9-14], studies, low bone mass is more common in patients with Crohn's disease (CD) than ulcerative colitis (UC).
Fracture — In some [15-17], but not all , population-based studies, there was an increased risk of fracture in individuals with IBD. In the largest study (6027 patients with IBD), the overall fracture rate was higher than that for controls (relative risk [RR] 1.4, 95% CI 1.3-1.6) . The increased risk occurred primarily in older (>60 years) patients. There was no difference between UC and CD. In another study, risk of fracture increased with duration of corticosteroid use .
- Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.
- van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006; :59.
- Compston J. Osteoporosis in inflammatory bowel disease. Gut 2003; 52:63.
- Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med 2009; 122:599.
- Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40:313.
- Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107:1031.
- Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114:902.
- Targownik LE, Bernstein CN, Nugent Z, Leslie WD. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol 2013; 11:278.
- Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992; 37:1396.
- Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108:417.
- Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228.
- Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10:250.
- Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004; 39:145.
- Lee SH, Kim HJ, Yang SK, et al. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol 2000; 15:512.
- Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133:795.
- Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46:176.
- Targownik LE, Bernstein CN, Nugent Z, et al. Inflammatory bowel disease and the risk of fracture after controlling for FRAX. J Bone Miner Res 2013; 28:1007.
- Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002; 123:468.
- Siffledeen JS, Siminoski K, Jen H, Fedorak RN. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007; 5:721.
- Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51:654.
- Stockbrügger RW, Schoon EJ, Bollani S, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002; 16:1519.
- Agrawal M, Arora S, Li J, et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 2011; 9:251.
- Shen B, Remzi FH, Oikonomou IK, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol 2009; 104:639.
- Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int 2012; 91:356.
- Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000; 119:909.
- Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis 2005; 11:325.
- Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479.
- Silvennoinen JA, Karttunen TJ, Niemelä SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71.
- Quint AR, Kaiser FE. Gonadotropin determinations and thyrotropin-releasing hormone and luteinizing hormone-releasing hormone testing in critically ill postmenopausal women with hypothyroxinemia. J Clin Endocrinol Metab 1985; 60:464.
- Odell WD. Testosterone treatment of men treated with glucocorticoids. Arch Intern Med 1996; 156:1133.
- Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83:1252.
- Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. Am J Clin Nutr 1991; 54:548.
- Lewis NR, Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. London (UK): British Society of Gastroenterology, 2007 www.guideline.gov/summary/summary.aspx?doc_id=14259 (Accessed on September 07, 2011).
- Atreja A, Aggarwal A, Licata AA, Lashner BA. Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. ScientificWorldJournal 2012; 2012:807438.
- Robinson RJ, Krzywicki T, Almond L, et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998; 115:36.
- Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10:777.
- Vogelsang H, Ferenci P, Resch H, et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7:609.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.
- Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119:639.
- Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101:119.
- Palomba S, Orio F Jr, Manguso F, et al. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 2005; 16:1141.
- von Tirpitz C, Klaus J, Steinkamp M, et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003; 17:807.
- Abitbol V, Briot K, Roux C, et al. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:1184.
- Hansen KE, Wilson HA, Zapalowski C, et al. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 2011; 26:1989.
- SKELETAL OUTCOMES
- Bone mineral density
- RISK FACTORS
- Disease-related inflammatory activity
- Glucocorticoid therapy
- Alterations in sex hormone status
- Vitamin D and calcium insufficiency
- Other nutritional deficiencies
- Assessment of clinical risk for fracture
- Interpretation of DXA
- BMD monitoring
- Laboratory evaluation
- Lifestyle measures
- Calcium and vitamin D
- Gonadal steroid replacement
- Pharmacologic therapy
- - Candidates for therapy
- - Choice of therapy
- - Efficacy
- Parathyroid hormone
- SUMMARY AND RECOMMENDATIONS